What is Prosigna?
Prosigna® is a test based on the genetic signature PAM50, which evaluates the expression or activity of 50 key genes in tumor tissue; allowing to estimate the risk of recurrence of the disease, and the intrinsic biological subtype. The result of the Prosigna test, interpreted in conjunction with other factors, is a prognostic indicator for patients who will be treated only with a hormonal treatment, not being required to administer chemotherapy.
Prosigna is the only genomic diagnostic test that identifies the Intrinsic Biological Subtype of Breast Cancer.
Classification of risk in low, intermediate and high, with a risk of recurrence in scale of 100 points, offers a greater range of personalized information very valuable prognosis to make decisions about the treatment of each patient.
It has validated scientifically in studies with more than 2400 patients.
Results are ready in just 10 working days.
How does it works?
The expression of 50 key genes is measured from the paraffin block tumour sample. This information is analysed by the Prosigna algorithm in conjunction with other variables such as tumour size and lymph node status.
Intrinsic subtype: according to the genetic analysis of the affected tissue, the type of cancer is classified into the 4 possible subtypes. It provides crucial information to offer the patient a personalized treatment.
ROR: Risk of recurrence or ROR is an index on a scale of 0 to 100, is based on the genetic information of the tumour; combined with the tumour size and the intrinsic subtype.
Risk classification: According to the obtained ROR and the number of affected nodes, it can be classified as low, intermediate and high.
Distant recurrence: it is a percentage that is calculated by combining the genetic estimators (ROR) and the intrinsic subtype obtained from the history of more than 2400 patients; it consists of the percentage of patients with the same lymph node status with distant recurrence in a period of 10 years.
The Prosigna® study is indicated for postmenopausal women surgically treated for stage I, II or IIIA breast cancer; with positive hormone receptors.